Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Monday that the company is collaborating with International Agencies (Bangladesh) Ltd. (IABL).
Under the collaboration, Eli Lilly is to provide its active pharmaceutical ingredient (API) for human insulin at a reduced price to International Agencies (Bangladesh) Ltd in an effort to raise patient access and improve affordability for high-quality insulin for around one million people living with diabetes in Bangladesh by 2030.
IABL is formulating, filling and finishing human insulin vials and cartridges under its own trademark and brand name by 2025. The IABL-developed insulin is being exclusively developed for the Bangladesh market.
Ilya Yuffa, Lilly International president, said, 'Lilly is committed to addressing the critical gaps in access to essential medicines for people living with diabetes in low- and middle-income countries. Through collaborations like this one with IABL, we are working to reduce barriers to access and ensure ongoing production and uninterrupted supply of insulin so that a greater number of patients can live healthier lives.'
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes